SynthesisFrontiers in pharmacology2026
The potential value of curcumin in breast cancer: a systematic review and meta-analysis of preclinical studies.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Curcumin has attracted considerable attention due to its multi-target anti-tumor properties and favorable safety profile. However, preclinical studies in breast cancer are challenged by considerable model heterogeneity and inconsistent findings. The objective of this study is to comprehensively evaluate the anti-tumor efficacy and safety of curcumin through systematic analysis and synthesis of animal experimental evidence, aiming to establish a theoretical foundation for clinical translation. Methods: Randomized controlled animal studies were systematically searched through PubMed, Web of Science, EMBASE, and the Cochrane Library up to 30 April 2025. Outcomes evaluated included tumor weight, tumor volume, cell proliferation (Ki-67 positivity), apoptosis (TUNEL positivity), liver and kidney function, and hematological indices. Results: Curcumin significantly reduced tumor weight (SMD = -1.65, 95% CI: -2.27 to -1.02, p < 0.00001) and volume (SMD = -2.47, 95% CI: -3.34 to -1.61, p < 0.00001). Curcumin also reduced the expression of Ki67 (SMD = -2.30, 95% CI: -3.58 to -1.01, p = 0.0005), The positive rate of TUNEL was increased (SMD = 2.10, 95% CI: 0.50 to 3.70, p = 0.01). Curcumin intervention did not significantly reduce liver and kidney function ALT (SMD = 0.15, 95% CI: -0.92 to 1.22, p = 0.79) AST (SMD = 0.14, 95% CI: -0.51 to 0.80, p = 0.66) Liver weight (SMD = 0.65, 95% CI: -0.23 to 1.53, P = 0.15), Creatinine (SMD = -0.93, 95% CI: -2.27 to 0.41, P = 0.18), BUN (SMD = -0.73, 95% CI: -2.59 to 1.14, P = 0.45). Conclusion: Curcumin demonstrates significant inhibitory effects on breast cancer growth and enhances apoptosis with favorable short-term safety in animal models. Further clinical trials are warranted to validate these findings in clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.